ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation

Area of Science:

• Hematology
• Immunology
• Transplantation Science

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a vital treatment for hematological diseases.
• Approximately 40-50% of HSCTs are performed across ABO blood group barriers due to independent inheritance.
• ABO incompatibility presents unique challenges in HSCT.

Purpose of the Study:

• To review the immune-hematological consequences of ABO-mismatched HSCT.
• To discuss strategies for preventing and managing complications.
• To highlight the importance of monitoring in ABO-mismatched HSCT outcomes.

Main Methods:

• Literature review of studies on ABO-mismatched HSCT.
• Analysis of immune-hematological consequences, including hemolytic complications and engraftment.
• Evaluation of data on graft-versus-host disease (GVHD), mortality, and survival.

Main Results:

• ABO-mismatched HSCT can lead to immediate and delayed hemolytic complications.
• Delayed red blood cell recovery and pure red cell aplasia are observed depending on the mismatch type.
• Inconsistent data exists regarding GVHD, mortality, and survival due to study limitations.

Conclusions:

• Knowledge of potential complications is key for early detection and efficient treatment.
• Proactive graft manipulation and transfusion support can mitigate risks.
• Close patient monitoring is essential to reduce fatal events in ABO-mismatched HSCT.